A drug combination tested for HR positive, HER2 negative breast cancer that has spread to the brain
Original title: Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, and the answers are not in yet.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether adding another drug to hormone therapy can help control breast cancer that has spread to the brain.
Who this trial is for. This trial is for people with HR positive, HER2 negative breast cancer that has spread to the brain, either newly found or grown after earlier treatment aimed at the brain. It is testing whether adding a drug called anlotinib to a drug called Culmerciclib and hormone therapy helps.
Where it stands. This trial has not reported results. It is measuring how well the drug combination works and how safe it is. The researchers hope it can help control the disease. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If this describes your cancer, this is something you could ask your care team about. They can help you decide if a trial like this is worth looking into for you.
What it doesn't mean: This does not mean the drug combination works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.